
Angelita Rebollo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3014791/publications.pdf Version: 2024-02-01



| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Isolation of Primary Hepatocytes for Testing Tumor Penetrating Peptides. Methods in Molecular Biology, 2022, 2383, 413-427. | 0.4 | 1 |
| 2 | PEPscan: A Broad Spectrum Approach for the Characterization of Protein-Binder Interactions?. Biomolecules, 2022, 12, 178. | 1.8 | 1 |
| 3 | Preclinical Validation of Tumor-Penetrating and Interfering Peptides against Chronic Lymphocytic Leukemia. Molecular Pharmaceutics, 2022, 19, 895-903. | 2.3 | 3 |
| 4 | Pepscan Approach for the Identification of Protein–Protein Interfaces: Lessons from Experiment. Biomolecules, 2021, 11, 772. | 1.8 | 4 |
| 5 | Bi-Functional Peptides as a New Therapeutic Tool for Hepatocellular Carcinoma. Pharmaceutics, 2021, 13, 1631. | 2.0 | 8 |
| 6 | Bifunctional Therapeutic Peptides for Targeting Malignant B Cells and Hepatocytes: Proof of Concept in Chronic Lymphocytic Leukemia. Advanced Therapeutics, 2020, 3, 2000131. | 1.6 | 13 |
| 7 | Identification of peptides interfering with the LRRK2/PP1 interaction. PLoS ONE, 2020, 15, e0237110. | 1.1 | 10 |
| 8 | Anti-tumoral Effect of a Cell Penetrating and Interfering Peptide Targeting PP2A/SET Interaction. Folia Medica, 2020, 62, 31-36. | 0.2 | 7 |
| 9 | New Therapeutic Approach for Targeting Hippo Signalling Pathway. Scientific Reports, 2019, 9, 4771. | 1.6 | 25 |
| 10 | Interfering peptides targeting protein–protein interactions: the next generation of drugs?. Drug Discovery Today, 2018, 23, 272-285. | 3.2 | 108 |
| 11 | Identification of PP2A/Set Binding Sites and Design of Interacting Peptides with Potential Clinical Applications. International Journal of Peptide Research and Therapeutics, 2018, 24, 479-488. | 0.9 | 12 |
| 12 | Identification and characterization of novel enhanced cell penetrating peptides for anti-cancer cargo delivery. Oncotarget, 2018, 9, 5944-5957. | 0.8 | 12 |
| 13 | Peptides derived from Plasmodium falciparum leucine-rich repeat 1 bind to serine/threonine phosphatase type 1 and inhibit parasite growth in vitro. Drug Design, Development and Therapy, 2018, Volume 12, 85-88. | 2.0 | 19 |
| 14 | Evaluation of Caspase-9b and PP2Acα2 as potential biomarkers for chronic lymphocytic leukemia. Biomarker Research, 2016, 4, 9. | 2.8 | 2 |
| 15 | Strategies to stabilize cell penetrating peptides for <i>in vivo</i> applications. Therapeutic Delivery, 2015, 6, 1171-1194. | 1.2 | 38 |
| 16 | Enhanced serum proteolysis resistance of cell-penetrating peptides. Therapeutic Delivery, 2015, 6, 139-147. | 1.2 | 11 |
| 17 | Cell Penetrating Peptides as a Therapeutic Strategy in Chronic Lymphocytic Leukemia. Protein and Peptide Letters, 2015, 22, 539-546. | 0.4 | 12 |
| 18 | Specific Targeting of Caspase-9/PP2A Interaction as Potential New Anti-Cancer Therapy. PLoS ONE, 2013, 8, e60816. | 1,1 | 28 |

Angelita Rebollo

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Deregulation of Aiolos expression in chronic lymphocytic leukemia is associated with epigenetic modifications. Blood, 2011, 117, 1917-1927. | 0.6 | 38 |
| 20 | Differential aiolos expression in human hematopoietic subpopulations. Leukemia Research, 2010, 34, 289-293. | 0.4 | 19 |
| 21 | Corrigendum to "Critical function of Ikaros in controlling Aiolos gene expression―[FEBS Lett. 581 (2007) 1605-1616]. FEBS Letters, 2009, 583, 1554-1554. | 1.3 | Ο |
| 22 | Differential epigenetic regulation of Aiolos expression in human tumoral cell lines and primary cells. FEBS Letters, 2008, 582, 457-467. | 1.3 | 5 |
| 23 | The Aiolos transcription factor is up-regulated in chronic lymphocytic leukemia. Blood, 2008, 111, 3225-3228. | 0.6 | 29 |
| 24 | Use of Penetrating Peptides Interacting with PP1/PP2A Proteins As a General Approach for a Drug Phosphatase Technology. Molecular Pharmacology, 2006, 69, 1115-1124. | 1.0 | 46 |
| 25 | Serine/threonine protein phosphatases PP1 and PP2A are key players in apoptosis. Biochimie, 2003, 85, 721-726 | 1.3 | 148 |